Evaluation of Serum and Tissue Cathepsin L in Non-segmental Vitiligo Patients
NCT06261073 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2024-02-15
Summary
Introduction Vitiligo is an autoimmune disease of the skin that targets pigment producing melanocytes and results in patches of depigmentation that are visible as white spots (Frisoli et al., 2020) Vitiligo is a relatively common acquired pigmentation disorder that can cause significant psychological stress (Leung AKC et al., 2021). The disease affects both genders equally, it can appear at any age, and the average age of onset is somewhat variable in different geographic (Majumder et al, 1993), with an estimated prevalence of 0.5-2% of the population in both adults and children worldwide (Krüger et al, 2012).
Vitiligo results in white macules and patches on the body. Initial lesions occur most frequently on the hands, forearms, feet, and face, favoring a periocular or perioral distribution (Ahmed jan N et al., 2023). Vitiligo lesions are classified into 2 major categories: segmental vitiligo (SV) and non-segmental vitiligo (NSV) (Relke et al ., 2019). Segmental vitiligo is characterized by its early onset, rapid stabilization, and unilateral distribution (Van Geel et al., 2017). Non-segmental vitiligo comprises of generalized (vitiligo vulgaris), acrofacial, mucosal (multifocal), and universal vitiligo (Kovacevic et al., 2016). Non-segmental vitiligo (NSV) is the most common form of vitiligo (Benzekri et al., 2013). Multiple mechanisms are involved in melanocyte disappearance, namely genetic predisposition, environmental triggers, metabolic abnormalities, impaired renewal, and altered inflammatory and immune responses (Boniface K et al ., 2018).
The results of some studies indicate a frequent association of vitiligo with autoimmune diseases. A number of studies have established a higher prevalence of autoimmune endocrine diseases in women, as well as in non-segmental vitiligo patients and in cases of family history of vitiligo and/or other autoimmune diseases. In addition, it was shown that the prevalence of endocrine diseases increases with increasing area of depigmentation (Troshina EA et al., 2020). Autoimmunity in vitiligo is driven by the IFN-γ-CXCL10 cytokine signaling pathway. Activated melanocyte-specific CD8+ T cells secrete IFN-γ, which signals through the IFN-γ receptor (IFN-γR) to activate JAK1/2 and STAT1. This induces the production of CXCL9 and CXCL10, which signal through their receptor CXCR3 to recruit more auto-reactive T cells to the epidermis, resulting in widespread melanocyte destruction (Harris JE et al., 2017).
The lysosomal cysteine proteinases of the papain family are involved in lysosomal bulk proteolysis, major histocompatibility complex class II-mediated antigen presentation, pro-hormone processing, and extracellular matrix remodeling.
Conditions
- Vitiligo
Interventions
- DIAGNOSTIC_TEST
-
blood sample and tissue biopsy
Serum level of Cathepsin L: 3 cm of blood will be taken on EDTA tubes from patients and control subjects and will be analyzed by double antibody sandwich enzyme-linked immune-sorbent assay (ELISA) to assess the level of CTSL in blood samples. Tissue expression of Cathepsin L: 5 mm punch biopsies will be taken under local anesthesia from lesions and from the adjacent normal skin of patients (from the lesional and peri-lesional sites). Also, skin biopsy of normal skin will be taken from healthy volunteers. The specimen of skin will be immediately placed in a formalin saline, and then immune-histochemical evaluation will be done to evaluate the CTSL expression in tissue.
Sponsors & Collaborators
-
Sohag University
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-03-15
- Primary Completion
- 2025-03-01
- Completion
- 2025-03-01
More Related Trials
-
The Investigation on the Expression of High Mobility Group Protein Box-1 (HMGB1) in Peripheral Blood of Vitiligo Patients and Healthy Controls According to Clinical Features, Treatment and Disease Activity
NCT03741738 ·Status: COMPLETED
-
Assessment of Hypoxia Inducible Factor and Autophagy Related Genes in Patients With Non-Segmental Vitiligo
NCT06410898 ·Status: RECRUITING ·Phase: NA
-
Study of Applications of Autologous Epidermal Cells in Liquid Phase in the Treatment of Vitiligo
NCT01511965 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Insulin Like Growth Factor-1 Against Oxidative Stress in Vitiligo
NCT05812079 ·Status: NOT_YET_RECRUITING
-
Vitiligo, New Treatment and Serum s100B
NCT06768840 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Dermoscopy in Nails
NCT06696612 ·Status: NOT_YET_RECRUITING
-
A Study to Evaluate the Efficacy of Microneedling as a Stand-alone Treatment for Vitiligo
NCT05053022 ·Status: COMPLETED ·Phase: NA
-
Thymic Stromal Lymphopoietin (TSLP) in Vitiligo
NCT03367273 ·Status: COMPLETED ·Phase: NA
-
Resident Memory T Cells in Vitiligo
NCT05223738 ·Status: UNKNOWN
-
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo
NCT04320160 ·Status: UNKNOWN ·Phase: NA
-
The Mechanism of Melanocyte Self-Assembly on Biomaterials and the Functional Analysis
NCT00509314 ·Status: UNKNOWN
-
Long-term Follow-up in Patients Affected With Acrofacial Vitiligo
NCT01459055 ·Status: UNKNOWN
-
Leucotrichia in Vitiligo
NCT03402633 ·Status: COMPLETED
-
IL35 Level in Vitiligo
NCT05980390 ·Status: UNKNOWN
-
Stress Response Pathways in Vitiligo
NCT02797574 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Serum Gasdermin D Level As a Potential Biomarker of Disease Activity in Vitiligo Patients
NCT06584643 ·Status: NOT_YET_RECRUITING
-
Questionnaire and Laboratory Data on Vitiligo Vulgaris
NCT01206374 ·Status: COMPLETED
-
Translational Assessment of Vitiligo According to Body Locations
NCT06068218 ·Status: COMPLETED ·Phase: NA
-
Sensory Symptoms in Active Vitiligo
NCT05390164 ·Status: UNKNOWN
-
The Gut and Skin Microbiome in Vitiligo Disease Progression
NCT03577327 ·Status: RECRUITING
-
Deciphering the Vitiligo Transcriptomic Signature Between Repigmented and Non Repigmented Lesions
NCT05927272 ·Status: RECRUITING ·Phase: NA
-
Analysis of Inflammation in the Vitiligo and Other Inflammatory Skin Diseases: Psoriasis, Atopic Dermatitis and Alopecia Areata
NCT03976622 ·Status: UNKNOWN
-
A Pilot Cohort Study of Risk Factors and Novel Methods of Skin Lesion Assessments in Adults With Atopic Dermatitis, Alopecia Areata, Psoriasis or Vitiligo
NCT06319781 ·Status: RECRUITING
-
Evaluation of Serological Markers of Vitiligo Activity
NCT06731283 ·Status: ACTIVE_NOT_RECRUITING
-
Autologous Non-cultured Epidermal Cell Suspension Transplantation in the Treatment of Vitiligo
NCT07187882 ·Status: RECRUITING ·Phase: NA